Fig. 2: Temozolomide promotes the secretion of APOE by pNETs to reshape lipid metabolism. | Cell Death & Disease

Fig. 2: Temozolomide promotes the secretion of APOE by pNETs to reshape lipid metabolism.

From: Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors

Fig. 2: Temozolomide promotes the secretion of APOE by pNETs to reshape lipid metabolism.The alternative text for this image may have been generated using AI.

A Intersection of the upregulated proteins in TMZ-treated BON1 with all secreted proteins recorded in the website (https://www.proteinatlas.org/) and present of the top 6 secreted proteins in TMZ-treated BON1 based on Log2fold change. B Heatmaps were generated to show the mRNA and protein expression of these top 6 secreted proteins in the DMSO and TMZ-treated cells from RNA-seq data (right) and Proteomics data (left), respectively. C Elisa results revealed that APOE level in the supernatant of the TMZ-treated BON1. D Elisa results revealed that APOE level in the supernatant of the TMZ-treated QGP1. E Representative images of IHC staining for APOE expression in pNET patients with TMZ therapy and drug-naïve patients from cohort 1. Score <3, low; Score ≥3 and <9, median; Score ≥9, high. Scale bar, 100 μm. F ELISA analysis indicated APOE levels of plasma samples in cohort 1. G APOE-receptors expression in TMZ-treated BON1 from RNA-seq data. H The expression of APOE-receptor SCARB1 on the TMZ-treated BON1 using cell fluorescence. Scale bar, 50 μm. I Impact of APOE knockdown on the change of TMZ-induced lipid droplets in BON1. Scale bar, 50 μm. J Impact of APOE knockdown on BON1 sensitivity to TMZ. Data in the graph are shown as the means ± SD from three independent experiment. *P < 0.05, **P < 0.01, ***P < 0.001, ns: no significance.

Back to article page